| 2021 |
Lee JH, Park J, Kim JH, Choi J-Y, Choi HJ, Ku EJ, Hong AR, Shin CS, Cho NH. Integrative analysis of genetic and clinical risk factors for bone loss in a Korean population. Bone. June 2021;147:115910. |
0 |
0 |
| 2012 |
Kim SW, Pajevic PD, Selig M, Barry KJ, Yang J-Y, Shin CS, Baek W-Y, Kim J-E, Kronenberg HM. Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. J Bone Miner Res. October 2012;27(10):2075-2084. |
32 |
31 |
| 2021 |
Imanishi Y, Ito N, Rhee Y, Takeuchi Y, Shin CS, Takahashi Y, Onuma H, Kojima M, Kanematsu M, Kanda H, Seino Y, Fukumoto S. Interim analysis of a phase 2 open‐label trial assessing burosumab efficacy and safety in patients with tumor‐induced osteomalacia. J Bone Miner Res. February 2021;36(2):262-270. |
2 |
1 |
| 2020 |
Kong SH, Kim JH, Park YJ, Lee JH, Hong AR, Shin CS, Cho NH. Low free T3 to free T4 ratio was associated with low muscle mass and impaired physical performance in community-dwelling aged population. Osteoporos Int. March 2020;31(3):525-531. |
0 |
0 |
| 2020 |
Lau EMC, Dinavahi R, Woo YC, Wu C-H, Guan J, Maddox J, Tolman C, Yang W, Shin CS. Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study. Osteoporos Int. April 2020;31(4):677-685. |
2 |
2 |